title: QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
abstract: A phase 2 study of eculizumab for treating myasthenia gravis (MG) used the quantitative myasthenia gravis score (QMG) and myasthenia gravis activities of daily living profile (MG-ADL) to evaluate baseline disease severity and treatment response. Correlations were then analyzed between these assessments.
  
  
  
  Patients were given eculizumab or placebo during the first 16-week treatment period of the crossover study, with treatment assignments reversed for the second treatment period following a 5-week washout. QMG and MG-ADL scores at baseline and endpoint of each treatment period generated correlation coefficients for baseline status and treatment response during eculizumab therapy.
  
  
  
  Correlation strength between QMG and MG-ADL scores was higher for treatment response (R = 0.726; 95% confidence interval, 0.264-0.907; P = 0.0036) than for assessing baseline disease status (R = 0.552; 95% confidence interval, -0.022-0.839; P = 0.0495).
  
  
  
  MG-ADL may be more sensitive for assessing treatment response than point-in-time disease status. Muscle Nerve 56: 328-330, 2017.
authors.affiliation: Department of Neurology, University of North Carolina, 2200 Physicians Office Building, CB 7025, 170 Manning Drive, Chapel Hill, North Carolina, USA.
authors.forename: James F
authors.identifier: 0000-0002-7136-8617
authors.initials: JF
authors.lastname: Howard
authors.affiliation: Department of Neurology, Ohio State University, Columbus, Ohio, USA.
authors.forename: Miriam
authors.initials: M
authors.lastname: Freimer
authors.affiliation: Medical Science and Development Operations, Alexion Pharmaceuticals, New Haven, Connecticut, USA.
authors.forename: Fanny
authors.initials: F
authors.lastname: O'Brien
authors.affiliation: Medical Science and Development Operations, Alexion Pharmaceuticals, New Haven, Connecticut, USA.
authors.forename: Jing Jing
authors.initials: JJ
authors.lastname: Wang
authors.affiliation: Connexion Healthcare, Newtown, Pennsylvania, USA.
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Collins
authors.affiliation: Department of Neurology, Ohio State University, Columbus, Ohio, USA.
authors.forename: John T
authors.initials: JT
authors.lastname: Kissel
mesh_terms: D000203:Activities of Daily Living / Q000523:psychology*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018592:Cross-Over Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000523:psychology*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C481642:eculizumab
keywords: eculizumab; myasthenia gravis; myasthenia gravis activities of daily living profile; patient-reported outcome; physician-reported outcome; quantitative myasthenia gravis